The Ocular Surface Characteristics in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td class="align_left"></td><td class="align_center">Ctrl</td><td class="align_center">ADT</td><td class="align_center">Symptomatic ADT group</td><td class="align_center">Asymptomatic ADT group</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td class="align_left">Demodex infection rate (%)</td><td class="align_center">60.00%</td><td class="align_center">70.00%</td><td class="align_center">100%</td><td class="align_center">57.14%</td></tr><tr><td class="align_left"><span style="width: 15.0284ptpx;"><svg height="11.6412pt" id="M62" style="vertical-align:-0.04979992pt" version="1.1" viewbox="-0.0498162 -11.5914 15.0284 11.6412" width="15.0284pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M748 650H522L515 622L546 617C580 611 587 604 565 575C518 513 469 451 419 393C376 474 349 534 330 580C318 609 325 612 361 618L383 622L392 650H151L144 622C214 616 224 612 257 543L360 327C270 218 187 124 159 95C106 40 92 34 26 28L17 0H252L259 28L236 31C189 37 188 47 209 78C249 136 308 210 377 294L478 79C494 44 487 37 449 32L418 28L409 0H673L680 28C596 34 591 39 554 116L436 361C526 469 574 521 604 553C659 612 669 614 739 622L748 650Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,9.945,-5.741)"><path d="M414 144C384 79 371 75 317 75H135L276 221C367 316 408 376 408 465C408 570 327 635 237 635C179 635 131 609 100 575L42 494L67 471C94 510 138 565 205 565C277 565 321 517 321 435C321 348 258 270 195 195C146 137 88 81 33 26V0H411C423 44 433 88 446 135L414 144Z"></path></g></svg></span></td><td class="align_center" colspan="2">0.53</td><td class="align_center" colspan="2">—</td></tr><tr><td class="align_left"><span style="width: 8.15071ptpx;"><svg height="8.68572pt" id="M63" style="vertical-align:-0.0498209pt" version="1.1" viewbox="-0.0498162 -8.6359 8.15071 8.68572" width="8.15071pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M600 480C600 590 528 650 384 650H143L137 622C222 614 225 607 210 531L130 127C113 41 106 36 23 28L17 0H294L300 28C204 36 195 42 212 127L243 284L314 263C327 263 339 263 352 264C465 271 600 337 600 480ZM508 481C508 351 402 304 329 304C289 304 265 311 250 317L295 559C302 594 310 606 323 611C335 616 350 619 367 619C455 619 508 573 508 481Z"></path></g></svg></span></td><td class="align_center" colspan="2">0.46<sup>a</sup></td><td class="align_center" colspan="2">0.029<sup>b</sup></td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Demodex infection rate among the groups.</div>

Disease Markers

tab2

Table 2

Table 2: The Ocular Surface Characteristics in Prostate Cancer Patients Treated with Androgen Deprivation Therapy 